Company news

Nurix Therapeutics, Inc. news in 2025

Nurix Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

December 7, 2025

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition

December 6, 2025

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annu...

December 5, 2025

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

November 30, 2025

Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

November 24, 2025

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

November 9, 2025

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

November 6, 2025

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

November 2, 2025

Nurix Therapeutics to Participate in Upcoming Investor Conferences

October 29, 2025

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

October 26, 2025

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock

October 21, 2025

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

October 21, 2025

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

October 17, 2025

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

October 8, 2025

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis

September 16, 2025

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

July 8, 2025

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia

July 6, 2025

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 12, 2025

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

June 12, 2025

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

June 5, 2025

Sanofi Exercises License Extension Option to Nurix’s STAT6 Program

June 1, 2025

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 27, 2025

Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

May 14, 2025

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

May 13, 2025

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

April 27, 2025

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

April 24, 2025

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

April 16, 2025

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

April 7, 2025

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

April 1, 2025

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

March 24, 2025

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

March 16, 2025

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors

March 12, 2025

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 3, 2025

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

January 27, 2025

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

January 21, 2025

Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases

January 12, 2025

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

Decks in 2025